Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Factor VIIa"" wg kryterium: Temat


Tytuł :
Recombinant activated factor VII for hemostasis in patients undergoing complex ascending aortic surgery: A single-center, single-surgeon retrospective analysis.
Autorzy :
Hang D; Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Koss K; Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Rokkas CK; Department of Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Pagel PS; Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.; Anesthesia Service, Clement J. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin, USA.
Pokaż więcej
Źródło :
Journal of cardiac surgery [J Card Surg] 2021 Dec; Vol. 36 (12), pp. 4558-4563. Date of Electronic Publication: 2021 Oct 04.
Typ publikacji :
Journal Article
MeSH Terms :
Factor VIIa*
Surgeons*
Hemostasis ; Humans ; Postoperative Hemorrhage/epidemiology ; Recombinant Proteins ; Retrospective Studies
Czasopismo naukowe
Tytuł :
A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding With Cardiac Surgery.
Autorzy :
Katz A; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Ahuja T; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Arnouk S; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Lewis TC; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Marsh K; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Papadopoulos J; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Merchan C; Department of Pharmacy, 12297NYU Langone Health, New York, NY, USA.
Pokaż więcej
Źródło :
Journal of intensive care medicine [J Intensive Care Med] 2022 Feb; Vol. 37 (2), pp. 231-239. Date of Electronic Publication: 2021 Jan 05.
Typ publikacji :
Journal Article
MeSH Terms :
Cardiac Surgical Procedures*
Factor VIIa*/therapeutic use
Blood Coagulation Factors/*therapeutic use
Hemorrhage/*drug therapy
Recombinant Proteins/*therapeutic use
Humans ; Retrospective Studies
Czasopismo naukowe
Tytuł :
A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost-utility analysis.
Autorzy :
Saiyarsarai P; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.; Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Robabpour Derakhshan A; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Khedmati J; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Eshghi P; Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seyedifar M; Pharmaceutical Management and Economics Research Center (PMERC), The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2021 Oct 08; Vol. 100 (40), pp. e27303.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antibodies, Bispecific/*economics
Antibodies, Monoclonal, Humanized/*economics
Factor VIIa/*economics
Hemophilia A/*drug therapy
Adult ; Antibodies, Bispecific/administration & dosage ; Antibodies, Monoclonal, Humanized/administration & dosage ; Child ; Child, Preschool ; Cost-Benefit Analysis ; Factor VIIa/administration & dosage ; Female ; Hemophilia A/economics ; Hemorrhage/prevention & control ; Humans ; Iran ; Male ; Quality-Adjusted Life Years ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/economics ; Young Adult
Czasopismo naukowe
Tytuł :
Very low-dose recombinant Factor VIIa administration for cardiac surgical bleeding reduces red blood cell transfusions and renal risk: a matched cohort study.
Autorzy :
Cotter E; Department of Anesthesiology, Division of Critical Care.
Sharma A; Department of Cardiology, University of Kansas Medical Center.
Campton A; University of Kansas Medical Center.
Gao G; Department of Biostatistics and Data Science.
He J; Department of Biostatistics and Data Science.
Wirtz K; Department of Quality Assurance.
Zorn T 3rd; Department of Cardiothoracic Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA.
Flynn BC; Department of Anesthesiology, Division of Critical Care.
Pokaż więcej
Źródło :
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2021 Oct 01; Vol. 32 (7), pp. 473-479.
Typ publikacji :
Journal Article
MeSH Terms :
Cardiac Surgical Procedures*/adverse effects
Erythrocyte Transfusion*
Blood Loss, Surgical/*prevention & control
Factor VIIa/*therapeutic use
Postoperative Complications/*prevention & control
Renal Insufficiency/*prevention & control
Adult ; Aged ; Aged, 80 and over ; Dose-Response Relationship, Drug ; Factor VIIa/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Postoperative Complications/etiology ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/therapeutic use ; Renal Insufficiency/etiology ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Structure of human factor VIIa-soluble tissue factor with calcium, magnesium and rubidium.
Autorzy :
Vadivel K; Department of Orthopaedic Surgery, University of California, Los Angeles, CA 90095, USA.
Schmidt AE; Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
Cascio D; DOE Institute for Genomics and Proteomics, University of California, Los Angeles, CA 90095, USA.
Padmanabhan K; Department of Biochemistry, Michigan State University, East Lansing, MI 48824, USA.
Krishnaswamy S; Division of Hematology, The Children's Hospital of Philadelphia University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Brandstetter H; Department of Biosciences, University of Salzburg, 5020 Salzburg, Austria.
Bajaj SP; Department of Orthopaedic Surgery, University of California, Los Angeles, CA 90095, USA.
Pokaż więcej
Źródło :
Acta crystallographica. Section D, Structural biology [Acta Crystallogr D Struct Biol] 2021 Jun 01; Vol. 77 (Pt 6), pp. 809-819. Date of Electronic Publication: 2021 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Factor VIIa*/chemistry
Factor VIIa*/metabolism
Calcium/*metabolism
Magnesium/*metabolism
Rubidium/*metabolism
Binding Sites ; Humans ; Protein Binding ; Protein Domains ; Recombinant Proteins/chemistry ; Recombinant Proteins/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Autorzy :
Kjalke M; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Kjelgaard-Hansen M; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Andersen S; Global Development, Novo Nordisk A/S, Bagsvaerd, Denmark.
Hilden I; Global Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Jul; Vol. 19 (7), pp. 1687-1696. Date of Electronic Publication: 2021 May 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor VIIa*
Hemophilia A*/drug therapy
Antibodies, Monoclonal, Humanized ; Blood Coagulation Factors ; Factor IX ; Factor VIII ; Humans ; Recombinant Proteins ; Thrombin
Czasopismo naukowe
Tytuł :
Weekly low-dose recombinant factor VIIa prophylaxis in Glanzmann thrombasthenia.
Autorzy :
Andiç N; Hematology Division, Osmangazi University Medical School, Meşelik Campus, Eskişehir, Turkey.
Oğuz N
Gündüz E
Kiraz Bulduk T
Üsküdar Teke H
Pokaż więcej
Źródło :
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis [Blood Coagul Fibrinolysis] 2021 Jul 01; Vol. 32 (5), pp. 349-351.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Factor VIIa/*therapeutic use
Hemorrhage/*etiology
Hemorrhage/*prevention & control
Thrombasthenia/*complications
Adult ; Dose-Response Relationship, Drug ; Factor VIIa/administration & dosage ; Humans ; Male ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Tytuł :
The intraoperative use of recombinant activated factor VII in arterial switch operations.
Autorzy :
Zink J; Texas Children's Hospital, Houston, TX, USA.
Spigel ZA; Texas Children's Hospital, Houston, TX, USA.
Ibarra C; Texas Children's Hospital, Houston, TX, USA.
Gottlieb EA; Dell Children's Medical Center of Central Texas, Austin, TX, USA.
Adachi I; Texas Children's Hospital, Houston, TX, USA.
Mery CM; Dell Children's Medical Center of Central Texas, Austin, TX, USA.
Imamura M; Texas Children's Hospital, Houston, TX, USA.
Heinle JS; Texas Children's Hospital, Houston, TX, USA.
McKenzie ED; Texas Children's Hospital, Houston, TX, USA.
Fraser CD; Dell Children's Medical Center of Central Texas, Austin, TX, USA.
Binsalamah ZM; Texas Children's Hospital, Houston, TX, USA.
Pokaż więcej
Źródło :
Cardiology in the young [Cardiol Young] 2021 Mar; Vol. 31 (3), pp. 386-390. Date of Electronic Publication: 2020 Nov 19.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Arterial Switch Operation*
Factor VIIa*/therapeutic use
Humans ; Pilot Projects ; Prospective Studies ; Recombinant Proteins ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Conformational Plasticity-Rigidity Axis of the Coagulation Factor VII Zymogen Elucidated by Atomistic Simulations of the N-Terminally Truncated Factor VIIa Protease Domain.
Autorzy :
Madsen JJ; Global and Planetary Health, College of Public Health, University of South Florida, Tampa, FL 33612, USA.
Olsen OH; Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Receptology, University of Copenhagen, Blegdamsvej 3b, DK-2200 Copenhagen, Denmark.
Pokaż więcej
Źródło :
Biomolecules [Biomolecules] 2021 Apr 08; Vol. 11 (4). Date of Electronic Publication: 2021 Apr 08.
Typ publikacji :
Journal Article
MeSH Terms :
Factor VII/*chemistry
Factor VIIa/*chemistry
Protein Precursors/*chemistry
Allosteric Regulation ; Catalytic Domain ; Cluster Analysis ; Factor VII/metabolism ; Factor VIIa/metabolism ; Humans ; Molecular Dynamics Simulation ; Principal Component Analysis ; Protein Precursors/metabolism ; Protein Structure, Tertiary ; Thromboplastin/chemistry ; Thromboplastin/metabolism ; Trypsin/metabolism
Czasopismo naukowe
Tytuł :
Use of recombinant activated factor VII for the treatment of perioperative bleeding in noncardiac surgery patients without hemophilia: A systematic review and meta-analysis of randomized controlled trials.
Autorzy :
Chang Z; Department of Surgical Intensive Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 1(st) Dahua Rd, Dongcheng District, Beijing 100730, PR China. Electronic address: .
Chu X; Department of Surgical Intensive Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 1(st) Dahua Rd, Dongcheng District, Beijing 100730, PR China.
Liu Y; Department of Surgical Intensive Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 1(st) Dahua Rd, Dongcheng District, Beijing 100730, PR China.
Liu D; Department of Critical Care Medicine, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Zhenjiang, Jiangsu 212001, PR China.
Feng Z; Department of Surgical Intensive Care Medicine, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, 1(st) Dahua Rd, Dongcheng District, Beijing 100730, PR China.
Pokaż więcej
Źródło :
Journal of critical care [J Crit Care] 2021 Apr; Vol. 62, pp. 164-171. Date of Electronic Publication: 2020 Dec 16.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; Systematic Review
MeSH Terms :
Factor VIIa*/adverse effects
Hemophilia A*/drug therapy
Humans ; Randomized Controlled Trials as Topic ; Recombinant Proteins
Czasopismo naukowe
Tytuł :
The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia.
Autorzy :
Poon MC; Department of Medicine, Pediatrics and Oncology, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.; Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Centre, Calgary, Alberta, Canada.
Pokaż więcej
Źródło :
Thrombosis and haemostasis [Thromb Haemost] 2021 Mar; Vol. 121 (3), pp. 332-340. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Clinical Trial; Journal Article; Observational Study
MeSH Terms :
Factor VIIa/*therapeutic use
Thrombasthenia/*drug therapy
Adolescent ; Adult ; Child ; Factor VIIa/adverse effects ; Female ; Hemorrhage/etiology ; Hemorrhage/prevention & control ; Humans ; Male ; Prospective Studies ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use ; Registries ; Thrombasthenia/complications ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency.
Autorzy :
Gorkom BL; Department of Hematology and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Radboud University Medical Center, Nijmegen, The Netherlands.
Holme PA; Department of Hematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Joch C; CSL Behring, Marburg, Germany.
Rogosch T; CSL Behring, Marburg, Germany.
Feussner A; CSL Behring, Marburg, Germany.
McKeand W; CSL Behring, King of Prussia, USA.
Roberts J; CSL Behring, King of Prussia, USA.
van Heerde W; Department of Hematology and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Radboud University Medical Center, Nijmegen, The Netherlands.; Department of Laboratory Medicine, Hematology Laboratory, Radboud University Medical Center, Nijmegen, Netherlands.; Enzyre, Novio Tech Campus, Nijmegen, The Netherlands.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2020 Dec; Vol. 25 (1), pp. 17-25.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Factor VII Deficiency/*drug therapy
Factor VIIa/*therapeutic use
Adult ; Blood Coagulation/drug effects ; Factor VII Deficiency/blood ; Factor VIIa/adverse effects ; Factor VIIa/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Recombinant Fusion Proteins/adverse effects ; Recombinant Fusion Proteins/blood ; Recombinant Fusion Proteins/pharmacology ; Recombinant Fusion Proteins/therapeutic use ; Recombinant Proteins/adverse effects ; Recombinant Proteins/blood ; Recombinant Proteins/pharmacology ; Recombinant Proteins/therapeutic use ; Serum Albumin, Human/adverse effects ; Serum Albumin, Human/analysis ; Serum Albumin, Human/pharmacology ; Serum Albumin, Human/therapeutic use ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
A serine loop in tissue factor mediates substrate selectivity by the tissue factor-factor VIIa complex.
Autorzy :
Birkle F; Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI, USA.
Morrissey JH; Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, MI, USA.; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Jan; Vol. 19 (1), pp. 75-84. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Factor VIIa*
Thromboplastin*
Factor IX ; Factor X ; Humans ; Serine
Czasopismo naukowe
Tytuł :
How the tissue factor-VIIa complex keeps two substrates in the loop.
Autorzy :
Schulman S; Divisions of Hemostasis and Thrombosis, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.; Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło :
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2021 Jan; Vol. 19 (1), pp. 52-54.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Comment
MeSH Terms :
Factor VIIa*
Thromboplastin*
Humans ; Serine
Czasopismo naukowe
Tytuł :
Successful treatment of acquired haemophilia A
Autorzy :
Kovács A; 1 Markhot Ferenc Oktatókórház és Rendelőintézet, Belgyógyászati Osztály, Eger, Knézich Károly u. 1., 3300.
Tajti B; 1 Markhot Ferenc Oktatókórház és Rendelőintézet, Belgyógyászati Osztály, Eger, Knézich Károly u. 1., 3300.
Szoboszlay I; 2 Markhot Ferenc Oktatókórház és Rendelőintézet, Központi Laboratórium, Eger.
Bereczky Z; 3 Debreceni Egyetem, Általános Orvostudományi Kar, Klinikai Központ, Laboratóriumi Medicina Intézet, Klinikai Laboratóriumi Kutató Tanszék, Debrecen.
Ilonczai P; 1 Markhot Ferenc Oktatókórház és Rendelőintézet, Belgyógyászati Osztály, Eger, Knézich Károly u. 1., 3300.
Pokaż więcej
Transliterated Title :
A szerzett haemophilia A sikeres kezelése.
Źródło :
Orvosi hetilap [Orv Hetil] 2021 Dec 05; Vol. 162 (49), pp. 1977-1981. Date of Electronic Publication: 2021 Dec 05.
Typ publikacji :
Journal Article
MeSH Terms :
Hemophilia A*/diagnosis
Hemophilia A*/therapy
Autoantibodies ; Blood Coagulation ; Factor VIIa ; Female ; Hemorrhage ; Humans
Czasopismo naukowe
Tytuł :
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors.
Autorzy :
Escobar M; Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
Castaman G; Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.
Boix SB; University and Polytechnic Hospital La Fe, Valencia, Spain.
Callaghan M; Central Michigan University, Detroit, Michigan, USA.
de Moerloose P; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Ducore J; Hematology/Oncology Clinic, University of California at Davis, Sacramento, California, USA.
Hermans C; Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Journeycake J; Oklahoma Bleeding and Clotting Disorders Center at OU Health, Oklahoma City, Oklahoma, USA.
Leissinger C; Section of Hematology/Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Luck J; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
Mahlangu J; Hemophilia Comprehensive Care Center, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
Miesbach W; Goethe University Hospital, Frankfurt, Germany.
Mitha IH; Lakeview Hospital, Benoni, Gauteng, South Africa.
Négrier C; Edouard Herriot University Hospital, Lyon, France.
Quon D; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
Recht M; American Thrombosis and Hemostasis Network, Rochester, New York, USA.; Oregon Health & Science University, Portland, Oregon, USA.
Schved JF; Haemophilia Treatment Centre, University Hospital Montpellier, Montpellier, France.
Shapiro AD; Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
Sidonio R Jr; Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA.
Srivastava A; Christian Medical College, Vellore, Tamil Nadu, India.
Stasyshyn O; Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine.
Vilchevska KV; National Specialized Children's Hospital Okhmatdyt, Kyiv, Ukraine.
Wang M; Hemophilia and Thrombosis Center, University of Colorado, Aurora, Colorado, USA.
Young G; Children's Hospital Los Angeles, Los Angeles, California, USA.; Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Alexander WA; Aoede Associates, Athens, Texas, USA.
Al-Sabbagh A; LFB-USA, Inc., Framingham, Massachusetts, USA.
Bonzo D; LFB-USA, Inc., Framingham, Massachusetts, USA.
Macie C; HEMA Biologics, LLC, Louisville, Kentucky, USA.
Wilkinson TA; GLOVAL LLC, Broomfield, Colorado, USA.
Kessler C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. 921-931. Date of Electronic Publication: 2021 Oct 11.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Hemophilia A*/drug therapy
Adult ; Child ; Cross-Over Studies ; Factor VIIa/adverse effects ; Hemostasis ; Humans ; Prospective Studies ; Recombinant Proteins
Czasopismo naukowe
Tytuł :
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors.
Autorzy :
Escobar M; Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
Luck J; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
Averianov Y; City Research and Development Center for Diagnostics and Treatment of Patients with Abnormal Hemostasis, Kyiv, Ukraine.
Ducore J; Hematology/Oncology Clinic, University of California at Davis, Sacramento, California, USA.
Fernández MFL; Hemostasis and Thrombosis Unit, Teresa Herrera Hospital, A Coruña, Spain.
Giermasz A; Division of Hematology/Oncology, University of California at Davis, Sacramento, California, USA.
Hart DP; The Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, QMUL, London, UK.
Journeycake J; Oklahoma Center for Bleeding and Clotting Disorders, Oklahoma City, Oklahoma, USA.
Kessler C; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, USA.
Leissinger C; Section of Hematology/Oncology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Mahlangu J; Hemophilia Comprehensive Care Center, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
Martinez LV; Dr. José Eleuterio González Monterrey University Hospital, Monterrey, Nuevo León, México.
Miesbach W; Goethe University Hospital, Frankfurt, Germany.
Mitha IH; Lakeview Hospital, Benoni, Gauteng, South Africa.
Quon D; Orthopaedic Hemophilia Treatment Center, Los Angeles, California, USA.
Reding MT; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Schved JF; Haemophilia Treatment Centre, University Hospital Montpellier, Montpellier, France.
Stasyshyn O; Institute of Blood Pathology and Transfusion Medicine, Lviv, Ukraine.
Vilchevska KV; National Specialized Children's Hospital Okhmatdyt, Kyiv, Ukraine.
Wang M; Hemophilia and Thrombosis Center, University of Colorado, Aurora, Colorado, USA.
Windyga J; Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Alexander WA; Aoede Associates, Athens, Texas, USA.
Al-Sabbagh A; LFB-USA, Inc., Framingham, Massachusetts, USA.
Bonzo D; LFB-USA, Inc., Framingham, Massachusetts, USA.
Mitchell IS; HEMA Biologics, LLC, Louisville, Kentucky, USA.
Wilkinson TA; GLOVAL LLC, Broomfield, Colorado, USA.
Hermans C; Cliniques Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Pokaż więcej
Źródło :
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2021 Nov; Vol. 27 (6), pp. 911-920. Date of Electronic Publication: 2021 Oct 06.
Typ publikacji :
Clinical Trial, Phase III; Journal Article
MeSH Terms :
Hemophilia A*/drug therapy
Hemostatics*/therapeutic use
Factor VIIa ; Hemostasis ; Humans ; Perioperative Care ; Recombinant Proteins
Czasopismo naukowe
Tytuł :
Use of rFVIIa in Preventing Recurrent Intra-articular Hemorrhages in a 15-Year-Old Patient With Glanzmann Thrombasthenia.
Autorzy :
Laguna P; Department of Oncology, Haematology, Bone Marrow Transplantation and Paediatrics, Medical University of Warsaw, Warsaw, Poland.
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2021 Nov 01; Vol. 43 (8), pp. e1120-e1123.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Factor VIIa/*administration & dosage
Hemorrhage/*prevention & control
Quadriceps Muscle/*pathology
Thrombasthenia/*complications
Adolescent ; Hemorrhage/etiology ; Hemorrhage/pathology ; Humans ; Male ; Prognosis ; Recombinant Proteins/administration & dosage
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies